In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 1.9 μM for antiviral activity; 1.7 μM for antimalarial activity
Beauvericin is a mycotoxin produced by various fungi including Fusarium spp. and Beaveria bassiana. As a cyclic hexadepsipeptide belonging to the enniatin antibiotic family, beauvericin contains three D-hydroxyisovaleryl and three N-methylphenylalanyl residues. Beauvericin was one of the active constituents of B. bassiana and was confirmed to have antibacterial and antifungal activities.
In vitro: Beauvericin has a strong antibacterial activity against human, animal and plant pathogenic bacteria, without selectivity between Gram-positive and Gram-negative bacteria. Unlike other antibiotics blocking the peptidoglycan biosynthesis, beauvericin does not target on the bacterial cell wall. Although it has broad-spectrum antibacterial activities, the antifungal activity of beauvericin is rarely reported as a single agent. Thus, the target of beauvericin is regarded to be different between bacteria and fungi and the activities of beauvericin need to be investigated against drug resistant bacteria .
In vivo: Previous study reported the the antifungal activity of beauvericin combined with miconazole or ketoconazole. Beauvericin at 0.5 mg/kg combined with ketoconazole at 0.5 mg/kg showed significant antifungal activity against Candida parapsilosis, which could cause high mortality rates quickly, particularly in neonates. In contrast, both beauvericin and ketoconazole alone have little to no inhibitory effect on C. parapsilosis .
Clinical trial: N/A
 Wang Q, Xu L. Beauvericin, a bioactive compound produced by fungi: a short review. Molecules. 2012 Feb 24;17(3):2367-77.
|Physical Appearance||A crystalline solid|
|Storage||Store at -20°C|
|Solubility||Soluble in DMSO|